BioNTech Se v. ModernaTX Inc

I. Executive Summary and Procedural Information

• Parties & Counsel:
  • Plaintiff: BioNTech SE (Germany)
  • Defendant: ModernaTX, Inc., Moderna, Inc. and Moderna US, Inc. (Delaware)
  • Plaintiff's Counsel: McCarter & English, LLP
• Case Identification: 1:26-cv-00183, D. Del., 02/19/2026
• Venue Allegations: Venue is alleged to be proper because the Defendant entities are organized under the laws of Delaware, and therefore reside in the district. The complaint also notes that Defendants have previously consented to venue in this district in other litigation.
• Core Dispute: Plaintiff alleges that Defendant's mNEXSPIKE® COVID-19 vaccine infringes a patent related to a "streamlined," domain-based mRNA vaccine design.
• Technical Context: The lawsuit concerns mRNA vaccine technology for preventing COVID-19, a field of immense global public health and commercial significance developed during the recent pandemic.
• Key Procedural History: The complaint notes an "extensive history of engaging in patent disputes" between the parties, including prior federal court litigations and an inter partes review (IPR) proceeding before the Patent Trial and Appeal Board, suggesting a high degree of familiarity between the parties regarding their respective intellectual property portfolios.

Case Timeline

Date	Event
2020-04-22	Earliest Priority Date for '899 Patent
2021-03-15	Moderna announces advancement of mRNA-1283 vaccine
2024-11-05	U.S. Patent No. 12,133,899 is issued
2025-05-30	FDA approves mRNA-1283 as mNEXSPIKE®
2026-02-19	Complaint for patent infringement is filed

II. Technology and Patent(s)-in-Suit Analysis

U.S. Patent No. 12,133,899: "Coronavirus Vaccine"

• Patent Identification: U.S. Patent No. 12,133,899 ("Coronavirus Vaccine"), issued November 5, 2024 (the "'899 Patent").

The Invention Explained

• Problem Addressed: The patent addresses the need for an effective vaccine against coronavirus infection '899 Patent, abstract The complaint elaborates that early mRNA vaccines, such as BioNTech's own COMIRNATY®, presented the complete "spike protein" of the SARS-CoV-2 virus to the immune system Compl. ¶2 The '899 Patent documents a different approach, conceiving of "alternative advanced technologies" that move beyond using the full-length protein Compl. ¶34
• The Patented Solution: The '899 Patent discloses a "streamlined" vaccine design that uses only select fragments, or domains, of the SARS-CoV-2 spike protein instead of the entire protein Compl. ¶2 Compl. ¶36 The core of the invention is an RNA construct that encodes the receptor-binding domain (RBD) of the spike protein, combined with a secretory signal and one or more domains to anchor or stabilize the resulting polypeptide, such as a transmembrane or trimerization domain Compl. ¶37 A diagram in the complaint illustrates this concept, showing a smaller, "streamlined, domain-based spike" as an alternative to the "full-length spike" Compl. p. 10 The patent specification discloses that mRNA constructs encoding "less than a full-length SARS-CoV-2 S protein, and particularly those that encode at least an RBD portion" can be effective as a vaccine '899 Patent, col. 14:23-28
• Technical Importance: This domain-based approach is alleged to trigger an equally strong immune response while being a fraction of the size, allowing the vaccine to be given at a lower dose and making it more stable during storage and transport (Compl. ¶¶2; Compl. 37).

Key Claims at a Glance

• The complaint asserts infringement of at least independent claim 1 of the '899 Patent Compl. ¶62
• The essential elements of independent claim 1 are recited as Compl. ¶42:
  • A pharmaceutical composition comprising a RNA that:
    • (i) includes modified uridines in place of all uridines, and
    • (ii) comprises a nucleotide sequence that encodes a polypeptide, wherein the polypeptide comprises:
      • (a) one or more fragments of a SARS-CoV-2 Spike (S) protein, wherein one of the fragments comprise a receptor binding domain (RBD),
      • (b) a secretory signal; and
      • (c) one or more additional domains selected from a trimerization domain, a transmembrane domain, and a combination thereof;
  • wherein the RBD is linked to one of the additional domains via a linker, and
  • wherein the linker comprises a GS linker.
• The complaint alleges infringement of "one or more claims," implicitly reserving the right to assert other claims, including dependent claims Compl. ¶10

III. The Accused Instrumentality

• Product Identification: The accused product is Moderna's mNEXSPIKE® (mRNA-1283) vaccine Compl. ¶5
• Functionality and Market Context:
  • mNEXSPIKE® is described in the complaint as a "streamlined vaccine design aim[ed] to target key parts of the spike protein rather than the entire spike protein, and at a lower dose" Compl. ¶5 A figure from a Moderna presentation is included in the complaint, describing the product as a "Next Generation COVID-19 Vaccine" with a "Lower mRNA dose" Compl. ¶49
  • Functionally, the complaint alleges that mNEXSPIKE® contains mRNA that encodes the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein Compl. ¶46 The complaint further alleges that the encoded polypeptide is attached via a linker to an influenza hemagglutinin transmembrane domain (HATM) that anchors it to the host cell membrane Compl. ¶47 A diagram included in the complaint, annotated by Plaintiff, depicts the mNEXSPIKE® product with a "Peptide Linker" and "Transmembrane anchor" Compl. ¶44
  • The complaint alleges mNEXSPIKE® is a commercially significant product for Moderna, expected to account for 55% of its COVID-19 vaccine sales in the 2025-2026 respiratory virus season Compl. ¶6

IV. Analysis of Infringement Allegations

'899 Patent Infringement Allegations

Claim Element (from Independent Claim 1)	Alleged Infringing Functionality	Complaint Citation	Patent Citation
A pharmaceutical composition comprising a RNA that: (i) includes modified uridines in place of all uridines, and	The accused mNEXSPIKE® vaccine is a pharmaceutical composition containing mRNA transcribed using N1-methyl-pseudouridine instead of uridine.	¶45	col. 9:40-41
(ii) comprises a nucleotide sequence that encodes a polypeptide, wherein the polypeptide comprises: (a) one or more fragments of a SARS-CoV-2 Spike (S) protein, wherein one of the fragments comprise a receptor binding domain (RBD),	The accused mNEXSPIKE® vaccine contains mRNA encoding the N-terminal domain (NTD) and the receptor-binding domain (RBD) of the SARS-CoV-2 spike protein.	¶46	col. 14:23-28
(b) a secretory signal; and	The accused mNEXSPIKE® vaccine's mRNA encodes the N-terminal domain (NTD), which is alleged to contain a secretory signal peptide.	¶46	col. 4:5-8
(c) one or more additional domains selected from a trimerization domain, a transmembrane domain, and a combination thereof;	The accused mNEXSPIKE® vaccine's polypeptide is attached to an influenza hemagglutinin transmembrane domain (HATM), which anchors the polypeptide to the host cell membrane.	¶47	col. 2:50-55
wherein the RBD is linked to one of the additional domains via a linker, and wherein the linker comprises a GS linker.	The linked NTD-RBD polypeptide in the accused mNEXSPIKE® vaccine is alleged to be attached via a linker to the transmembrane domain, which the complaint alleges comprises a GS linker.	¶47	col. 4:13-17

• Identified Points of Contention:
  • Scope Questions: A central question may be whether the accused mNEXSPIKE® product, which is alleged to contain mRNA encoding both an N-terminal domain (NTD) and a receptor-binding domain (RBD) Compl. ¶46, meets the claim limitation of "one or more fragments of a SARS-CoV-2 Spike (S) protein, wherein one of the fragments comprise a receptor binding domain (RBD)." The construction of "one or more fragments" will be critical.
  • Technical Questions: The complaint alleges the accused product's NTD "contains a secretory signal peptide" Compl. ¶46 The claim requires "a secretory signal." A point of contention could be whether an entire protein domain that contains a signal is equivalent to the claimed "secretory signal" itself. Another visual from the complaint depicts the components of the streamlined design, highlighting the "RBD," "Trimerization domain," and "Transmembrane domain" as distinct functional parts Compl. p. 11

V. Key Claim Terms for Construction

• The Term: "secretory signal"
• Context and Importance: This term is critical because the complaint alleges the accused product contains an "N-terminal domain ('NTD') that contains a secretory signal peptide" Compl. ¶46, rather than just the signal peptide itself. The infringement analysis will depend on whether this larger structure falls within the scope of the claimed "secretory signal." Practitioners may focus on this term because its construction will determine if the patent covers constructs that include the signal peptide as part of a larger functional domain like the NTD.
• Intrinsic Evidence for Interpretation:
  • Evidence for a Broader Interpretation: The patent specification broadly describes that a "secretory signal peptide (sec) may be fused to the antigen-encoding regions" '899 Patent, col. 4:5-8, without strictly limiting its implementation to a standalone element.
  • Evidence for a Narrower Interpretation: Figures in the patent, such as Figure 30, depict the "sec" element as a discrete, separate component of the RNA construct, which could support an argument that the term refers to the signal peptide alone and not a larger domain containing it.

VI. Other Allegations

• Indirect Infringement: The complaint alleges active inducement of healthcare practitioners based on Moderna's labeling and instructions to "Administer mNEXSPIKE® intramuscularly" Compl. ¶59 It also alleges contributory infringement by supplying components of mNEXSPIKE®, such as the mRNA and lipid particles, knowing they are not staple articles of commerce and are especially made for infringing use Compl. ¶60
• Willful Infringement: Willfulness is alleged based on Moderna's knowledge of the '899 Patent since at least its issue date of November 5, 2024 Compl. ¶51 The complaint further alleges that Moderna "routinely monitors BioNTech's patent applications," suggesting pre-suit awareness of the technology Compl. ¶52

VII. Analyst's Conclusion: Key Questions for the Case

• A core issue will be one of definitional scope: can the claim term "a secretory signal" be construed to read on the accused product's "N-terminal domain (NTD) that contains a secretory signal peptide"? The case may turn on whether providing a larger functional domain that includes the signal is equivalent to providing the signal itself as claimed.
• A key evidentiary question will be one of structural correspondence: does the accused vaccine's linked NTD-RBD structure constitute "one or more fragments of a SARS-CoV-2 Spike (S) protein" as required by Claim 1? The court will likely need to determine if this specific combination of domains, as used by Moderna, falls within the patented concept of a "streamlined, domain-based" vaccine.
• A third central question will relate to infringement and damages: given the parties' extensive litigation history and Moderna's alleged monitoring of BioNTech's patent filings, the court will likely face significant questions regarding willfulness, particularly concerning whether Moderna's conduct post-issuance of the '899 Patent was objectively reckless.